Surrozen, Inc. (NASDAQ:SRZN – Get Rating) was the target of a significant growth in short interest in December. As of December 30th, there was short interest totalling 279,700 shares, a growth of 188.4% from the December 15th total of 97,000 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 678,900 shares, the days-to-cover ratio is currently 0.4 days.
Surrozen Stock Up 4.5 %
Shares of Surrozen stock opened at $0.65 on Wednesday. The stock has a market cap of $22.75 million, a PE ratio of -0.48 and a beta of -0.24. Surrozen has a 12 month low of $0.34 and a 12 month high of $4.82. The business has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $1.98.
Get
Surrozen alerts:
Surrozen (NASDAQ:SRZN – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Analysts expect that Surrozen will post -1.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Surrozen
Several institutional investors and hedge funds have recently modified their holdings of SRZN. Bank of Montreal Can purchased a new position in Surrozen in the first quarter valued at about $377,000. FMR LLC bought a new stake in shares of Surrozen in the 2nd quarter valued at approximately $744,000. Vanguard Group Inc. increased its holdings in Surrozen by 3.2% in the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company's stock worth $984,000 after buying an additional 15,299 shares during the last quarter. Finally, Board of Trustees of The Leland Stanford Junior University lifted its stake in Surrozen by 3,102.9% in the third quarter. Board of Trustees of The Leland Stanford Junior University now owns 781,960 shares of the company's stock valued at $1,580,000 after acquiring an additional 757,546 shares during the last quarter. 62.13% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on SRZN shares. Bank of America cut shares of Surrozen from a "neutral" rating to an "underperform" rating in a research note on Wednesday, November 16th. JPMorgan Chase & Co. downgraded Surrozen from a "neutral" rating to an "underweight" rating in a report on Tuesday, November 29th. Finally, Guggenheim downgraded Surrozen from a "buy" rating to a "neutral" rating in a report on Friday, November 18th.
Surrozen Company Profile
(Get Rating)
Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Featured Stories
- Get a free copy of the StockNews.com research report on Surrozen (SRZN)
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
